Dynavax Reports HEPLISAV BLA Submission
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has submitted a U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.